Keytruda combo cleared as first-line kidney cancer treatment in EUMerck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in Share XKeytruda combo cleared as first-line kidney cancer treatment in EUhttps://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/
Immunicum shares fall despite “fantastic” kidney cancer dataShares in Swedish biotech Immunicum dipped sharply after it reported phase 2 results with its lead dendritic cell Share XImmunicum shares fall despite “fantastic” kidney cancer datahttps://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
Roche pulls extended use application for kidney cancer drugRoche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy Share XRoche pulls extended use application for kidney cancer drughttps://pharmaphorum.com/news/roche-pulls-extended-use-application-for-kidney-cancer-drug/
EU approves Ipsen’s Cabometyx in second line liver cancerThe European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The Share XEU approves Ipsen’s Cabometyx in second line liver cancerhttps://pharmaphorum.com/news/european-commission-cabometyx/
ESMO round-up: Big win for AstraZeneca in ovarian cancer, and moreSeveral drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich. Share XESMO round-up: Big win for AstraZeneca in ovarian cancer, and morehttps://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/
